Pathology of C4d-negative antibody-mediated rejection in renal allografts

Current Opinion in Organ Transplantation

Volumn 18, Issue 3, 2013, Pages 319-326

  Haas, Mark ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Complement C4d; Donor specific antibodies; Humoral rejection; Renal transplantation; Transplant glomerulopathy

Indexed keywords

COMPLEMENT COMPONENT C4D; CORTICOSTEROID; IMMUNOGLOBULIN; RITUXIMAB; THYMOCYTE ANTIBODY; ALLOANTIBODY; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; PEPTIDE FRAGMENT;

ANTIBODY MEDIATED REJECTION; CAPILLARITIS; CORTICOSTEROID THERAPY; DRUG MEGADOSE; GLOMERULITIS; GLOMERULOPATHY; GRAFT FAILURE; HISTOLOGY; HUMAN; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FIBROSIS; PLASMAPHERESIS; REVIEW; ALLOTRANSPLANTATION; BLOOD; DONOR; GRAFT REJECTION; HUMORAL IMMUNITY; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PATHOLOGY;

COMPLEMENT C4B; GRAFT REJECTION; HUMANS; IMMUNITY, HUMORAL; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PEPTIDE FRAGMENTS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

MLCS; MLOWN;

EID: 84879933836     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32835d4daf     Document Type: Review

References (44)

1. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008; 86:377-383.
2. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18:1046-1056.
3. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10:464-471.
4. Halloran PF, Wadgymar A, Ritchie S, et al. The significance of the anticlass I antibody response. I. Clinical and pathologic features of anticlass I-mediated rejection. Transplantation 1990; 49:85-91.
5. Halloran PF, Schlaut J, Solez K, et al. The significance of the anticlass I antibody response. II. Clinical and pathologic features of renal transplants with anticlass I-like antibody. Transplantation 1992; 53:550-555.
6. Trpkov K, Campbell P, Pazderka F, et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody: analysis using the Banff grading schema. Transplantation 1996; 61:1586-1592.
7. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int 2003; 63:1888-1893.
8. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10:1517-1523.
9. Randhawa PS, Shapiro R, Jordan ML, et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Am J Surg Pathol 1993; 17:60-68.
10. Trimarchi HM, Truong LD, Brennan S, et al. FK506-associated thrombotic microangiopathy. Transplantation 1999; 67:539-544.
11. Meehan SM, Baliga R, Poduval R, et al. Platelet CD61 expression in vascular calcineurin inhibitor toxicity of renal allografts. Hum Pathol 2008; 39:550-556.
12. Satoskar AA, Pelletier R, Adams P, et al. De novo thrombotic microangiopathy in renal allograft biopsies: role of antibody-mediated rejection. Am J Transplant 2010; 10:1804-1811.
13. Meehan SM, Kremer J, Ali FN, et al. Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies. Clin J Am Soc Nephrol 2011; 6:395-403.
14. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12:574-582.
15. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380.
16. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7:2124-2132.
17. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86:464-470.
18. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214.
19. Regele H, Exner M, Watschinger B, et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16:2058-2066.
20. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13:779-787.
21. Bohmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13:1091-1099.
22. Herzenberg AM, Gill JS, Djurdjev O, et al. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol 2002; 13:234-241.
23. Nickeleit V, Zeiler M, Gudat F, et al. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13:242-251.
24. Mengel M, Bogers J, Bosmans J-L, et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant 2005; 5:1050-1056.
25. Tan CD, Sokos GG, Pidwell DJ, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant 2009; 9:2075-2084.
26. de Kort H, Munivenkatappa RB, Berger SP, et al. Pancreas allograft biopsies with positive C4d staining and antidonor antibodies related to worse outcome for patients. Am J Transplant 2010; 10:1660-1667.
27. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria: an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3:708-714.
28. Berry GJ, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant 2011; 30:601-611.
29. Drachenberg CB, Torrealba JR, Nankivell BG, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts: updated Banff grading schema. Am J Transplantation 2011; 11:1792-1802.
30. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9:2312-2323.
31. Cosio FG, Gloor JM, Sethi S, et al. Transplant glomerulopathy. Am J Transplant 2008; 8:492-496.
32. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9:2561-2570.
33. Wavamunno MD, O'Connell PJ, Vitalone M, et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant 2007; 7:1-12.
34. Baid S, Pascual M, Williams WW Jr, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10:146-153.
35. Baid-Agrawal S, Farris AB III, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80:879-885.
36. Haas M, Mirocha J. Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy. Am J Transplant 2011; 11:2123-2131.
37. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713-723.
38. Botermans JM, de Kort H, Eikmans M, et al. C4d staining in renal allograft biopsies with early acute rejection and subsequent clinical outcome. Clin J Am Soc Nephrol 2011; 6:1207-1213.
39. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11:56-65.
40. de Kort, H, Willicombe M, Brookes P, et al. Microcirculation inflammation associateswith outcomeinrenaltransplant patients withdenovo donor-specific antibodies. Am J Transplant. 2012; doi:10.111/j.1600.6143.2012.04325.x. [Epub ahead of print]
41. Verghese P, Dunn T, Najafian B, et al. The impact of C4d and microvascular inflammation before we knew them. Clinical Transplant. (in press).
42. Mengel M, Sis B, Haas M, et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12:563-570.
43. Haas M. C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. Clin Nephrol 2011; 75:271-278.
44. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12:1168-1179.